Acrivon Therapeutics (NASDAQ:ACRV) unveiled promising interim data from its lead oncology program on Thursday, demonstrating that its biomarker-driven approach can achieve significant results in patients with hard-to-treat serous endometrial cancer.
The company’s lead candidate, ACR-368, a selective CHK1/2 inhibitor, showed a 67% confirmed objective response rate (cORR) in a subset of patients identified by Acrivon’s proprietary "OncoSignature" biomarker.
Across a broader group of serous endometrial cancer patients, the drug achieved a 52% cORR, a notable figure for a population that has typically failed multiple lines of prior therapy, including chemotherapy and immunotherapy.
"These results are consistent with serous tumors being G1-S-deficient, leading to a dependency on the G2-M checkpoint controlled by CHK1/2," the company said.
To accelerate the drug's path to market, Acrivon has submitted a Phase 3 protocol for a combination study with anti-PD-1 therapy and plans to open more than 20 clinical sites across Germany, Italy, France, and Spain in early 2026.
Beyond its lead asset, Acrivon reported initial Phase 1 success for ACR-2316, a dual WEE1/PKMYT1 inhibitor.
In a study of 33 patients, the drug induced tumor shrinkage in nearly half of the evaluable subjects at higher dose levels, including a confirmed partial response in endometrial cancer.